Halozyme Therapeutics, Inc. HALO was a big mover last session, as the company saw its shares rise almost 18% on the day. The upside was driven after the company announced robust phase 2 results for its pancreatic cancer drug, PEGPH20. The news also led to far more shares changing hands than in a normal session, resulting in solid volume. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.88 to $11.88 in the past one-month time frame.
None of the estimates for this stock were revised in the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday’s action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Halozyme Therapeutics carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the same industry is Windtree Therapeutics, Inc. WINT, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is HALO going up? Or down? Predict to see what others think: Up or Down
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment